Nilotinib monohydrochloride monohydrateCAS# 923288-90-8 |
- Imatinib Mesylate (STI571)
Catalog No.:BCC1115
CAS No.:220127-57-1
- Dasatinib (BMS-354825)
Catalog No.:BCC1281
CAS No.:302962-49-8
- Saracatinib (AZD0530)
Catalog No.:BCC1166
CAS No.:379231-04-6
- Nilotinib(AMN-107)
Catalog No.:BCC3643
CAS No.:641571-10-0
- Ponatinib (AP24534)
Catalog No.:BCC2522
CAS No.:943319-70-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 923288-90-8 | SDF | Download SDF |
| PubChem ID | 16757572 | Appearance | Powder |
| Formula | C28H25ClF3N7O2 | M.Wt | 583.99 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | AMN107 | ||
| Solubility | DMSO : ≥ 33 mg/mL (56.51 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;hydrate;hydrochloride | ||
| SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5.O.Cl | ||
| Standard InChIKey | YCBPQSYLYYBPDW-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C28H22F3N7O.ClH.H2O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38;;/h3-16H,1-2H3,(H,35,39)(H,33,36,37);1H;1H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly more potent against BCR-ABL than Imatinib, and is active against many Imatinib-resistant BCR-ABL mutants.In Vitro:The novel, selective Abl inhibitor, Nilotinib (AMN107), is designed to interact with the ATP-binding site of BCR-ABL with a higher affinity than Imatinib. In addition to being significantly more potent compared with Imatinib (IC50<30 nM), Nilotinib also maintains activity against most of the BCR-ABL point mutants that confer Imatinib resistance[1]. Nilotinib demonstrates significant antitumor efficacy against GIST xenograft lines and Imatinib-resistant GIST cell lines. The parent cell lines GK1C and GK3C show Imatinib sensitivity with IC50 of 4.59±0.97 µM and 11.15±1.48 µM, respectively. The Imatinib-resistant cell lines GK1C-IR and GK3C-IR show Imatinib resistance with IC50 values of 11.74±0.17 µM (P<0.001) and 41.37±1.07 µM (P<0.001), respectively[2].In Vivo:The percentage of tumor growth inhibition (TGI) is 83.8% for Imatinib and 69.6% for Nilotinib in the GK1X xenograft line (n.s.). In the GK2X xenograft line, TGI is 83.0% for Imatinib and 85.3% for Nilotinib (n.s.). Additionally, the GK3X xenograft line TGI is 31.1% for Imatinib and 47.5% for Nilotinib (n.s.). These results suggest that, except for the GK1X xenograft line, Nilotinib shows equivalent or higher antitumor effects than Imatinib[2]. Nilotinib has a significant healing effect on the macroscopic and microscopic pathologic scores and ensures considerable mucosal healing in the indomethacin-induced enterocolitis rat model. While Nilotinib decreased the PDGFR α and β levels and apoptotic scores in the colon, it did not have a significant effect on the weight and TNF-α levels. Further experimental investigations could provide more definitive evidence for humans[3]. References: | |||||
Nilotinib monohydrochloride monohydrate Dilution Calculator
Nilotinib monohydrochloride monohydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7124 mL | 8.5618 mL | 17.1236 mL | 34.2472 mL | 42.809 mL |
| 5 mM | 0.3425 mL | 1.7124 mL | 3.4247 mL | 6.8494 mL | 8.5618 mL |
| 10 mM | 0.1712 mL | 0.8562 mL | 1.7124 mL | 3.4247 mL | 4.2809 mL |
| 50 mM | 0.0342 mL | 0.1712 mL | 0.3425 mL | 0.6849 mL | 0.8562 mL |
| 100 mM | 0.0171 mL | 0.0856 mL | 0.1712 mL | 0.3425 mL | 0.4281 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Nilotinib is a inhibitor of BCR-ABL, IC50 < 30nM; for the treatment of chronic myelogenous leukemia.
- Opicapone
Catalog No.:BCC6545
CAS No.:923287-50-7
- SAR407899 hydrochloride
Catalog No.:BCC5592
CAS No.:923262-96-8
- Refametinib R enantiomer
Catalog No.:BCC4055
CAS No.:923032-38-6
- Refametinib
Catalog No.:BCC4276
CAS No.:923032-37-5
- 3-O-Methyl-3-methoxymaxterone
Catalog No.:BCC8639
CAS No.:92282-70-7
- Sanggenon N
Catalog No.:BCN4846
CAS No.:92280-12-1
- (±)-MDMA hydrochloride
Catalog No.:BCC5965
CAS No.:92279-84-0
- Daphnilongeridine
Catalog No.:BCN4460
CAS No.:922522-15-4
- Syringin pentaacetate
Catalog No.:BCN4459
CAS No.:92233-55-1
- 5,6-Desmethylenedioxy-5-methoxyaglalactone
Catalog No.:BCN7639
CAS No.:922169-96-8
- GlcNAcstatin
Catalog No.:BCC5334
CAS No.:922163-64-2
- SCH 529074
Catalog No.:BCC6131
CAS No.:922150-11-6
- SAR407899
Catalog No.:BCC5593
CAS No.:923359-38-0
- ABT-263 (Navitoclax)
Catalog No.:BCC1272
CAS No.:923564-51-6
- GSK962040
Catalog No.:BCC4163
CAS No.:923565-21-3
- GSK962040 hydrochloride
Catalog No.:BCC4152
CAS No.:923565-22-4
- Vaniprevir
Catalog No.:BCC2030
CAS No.:923590-37-8
- Simeprevir
Catalog No.:BCC1949
CAS No.:923604-59-5
- 3-Acetoxy-4-cadinen-8-one
Catalog No.:BCN4461
CAS No.:923950-05-4
- DUBs-IN-3
Catalog No.:BCC5258
CAS No.:924296-17-3
- DUBs-IN-1
Catalog No.:BCC5256
CAS No.:924296-18-4
- DUBs-IN-2
Catalog No.:BCC5257
CAS No.:924296-19-5
- HBX 41108
Catalog No.:BCC6137
CAS No.:924296-39-9
- AdipoRon
Catalog No.:BCC4756
CAS No.:924416-43-3
